Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Frank Burrell
Scientific Storytelling

Liz Kane
Impactful Strategy